Pharmacokinetics in real life: Sex and gender differences

Journal of Population Therapeutics and Clinical Pharmacology

Volumn 20, Issue 3, 2013, Pages

  Mattison, Donald R ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Adverse drug events; Adverse drug reactions; Bioequivalence; Drug disposition; Pharmacodynamics; Pharmacokinetics; Sex differences

Indexed keywords

ALPRAZOLAM; AMLODIPINE; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; CARDIOVASCULAR AGENT; DIGOXIN; FIBRINOLYTIC AGENT; MIDAZOLAM; NIFEDIPINE; PLACEBO; TRIAZOLAM; VERAPAMIL; ZOLPIDEM;

AREA UNDER THE CURVE; ARTICLE; BODY COMPOSITION; BODY MASS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG INDUCED DISEASE; ENDOCRINOLOGY; GENDER; HEART FAILURE; HEART RATE; HUMAN; IMMUNE RESPONSE; INCIDENCE; LIFE; META ANALYSIS (TOPIC); METABOLISM; PERSONALIZED MEDICINE; PHYSIOLOGY; POLYPHARMACY; PREGNANCY; PROTEIN BINDING; RISK FACTOR; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT;

EID: 84887329177     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Schwartz JB. Drug metabolism. In: Legato MJ, Bilezikian JP (eds). Principles of Gender-Specific Medicine. Amsterdam; Boston: Elsevier Academic Press, 2004.
2. U.S. Food and Drug Administration. Zolpidem Containing Products: Drug Safety Communication-FDA Requires Lower Recommended Doses. (January 10, 2013) http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm334738.htm (May 15, 2013).
3. ICRP, 2002. Basic Anatomical and Physiological Data for Use in Radiological Protection Reference Values. ICRP Publication 89. Ann ICRP. 32:3-4.
4. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.177.1662&rep=rep1&type=pdf (May 21, 2013)
5. Barquín J, Luna Jde D, Hernández AF. A controlled study of the time-course of breath alcohol concentration after moderate ingestion of ethanol following a social drinking session. Forensic Sci Int 2008;177(2-3):140-145.
6. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167(16):1752-1759.
7. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol 1998;38(11):1003-1009.
8. Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German university hospitals. Drug Saf 2008;31(9):789-798.
9. Evans RS, Lloyd JF, Stoddard GJ, Nebeker JR, Samore MH. Risk factors for adverse drug events: a 10-year analysis. Ann Pharmacother 2005;39(7-8):1161-1168.
10. Mattison Faye ACM, Mattison DR. Drug disposition and effect. In: Schenck-Gustafsson K, DeCola PR, Pfaff DW, Pisetsky DS, eds. Handbook of Clinical Gender Medicine. Basel: Karger, 2012:473-479.
11. United States General Accounting Office. Drug safety: most drugs withdrawn in recent years had greater health risks for women. GAO-01-286R Drugs Withdrawn From Market. January 19, 2001. http://www.gao.gov/assets/100/90642.pdf (June 15, 2013)
12. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf 2007;2(1):79-87.
13. Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. J Womens Health Gend Based Med 2002;11(7):601-615.
14. Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part II. J Womens Health Gend Based Med 2002;11(7):617-629.
15. Legato MJ. Gender-specific medicine: the view from Salzburg. Gend Med 2004;1(2):61-63.
16. Legato MJ. The skewed sex distribution in affective disorders--a diagnostic, social, or biological problem? Prog Brain Res 2010;186:159-166.
17. Poon S, Goodman SG, Yan RT, Bugiardini R, Bierman AS, Eagle KA, Johnston N, Huynh T, Grondin FR, Schenck-Gustafsson K, Yan AT. Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. Am Heart J 2012;163(1):66-73.
18. Wizemann TM, Pardue M-L (eds). Exploring the Biological Contributions to Human Health: Does Sex Matter? Report of the Institute of Medicine. Washington, DC: National Academy Press, 2001.
19. Federman DD. The biology of human sex differences. N Engl J Med. 2006;354(14):1507-1514.
20. Mattison D, Zajicek A. Gaps in knowledge in treating pregnant women. Gend Med 2006;3(3):169-182.
21. Gray J. Why can't a woman be more like a man? Clin Pharmacol Ther 2007;82(1):15-17.
22. Abad-Santos F, Novalbos J, Gálvez-Múgica MA, Gallego-Sandín S, Almeida S, Vallée F, García AG. Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharmacol Res 2005;51(5):445-452.
23. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009;48(3):143-157. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644551/ (May 26, 2013)
24. Chen M-L, Lee S-C, Ng M-J, Schuirmann DJ, Lesko LJ, Williams RL. Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 2000;68(5):510-521.
25. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002;41(5):329-342.
26. Greenblatt DJ, von Moltke LL. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 2008;48(11):1350-1355.
27. Hu ZY, Zhao YS. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis. Drug Metab Dispos 2010;38(5):817-812. http://dmd.aspetjournals.org/content/38/5/817.long (May 28, 2013)
28. Chetty M, Mattison D, Rostami-Hodjegan A. Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. Curr Drug Metab 2012 Jul;13(6):778-786.
29. Aarnoudse AL, Dieleman JP, Stricker BH. Age-and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf 2007;30(5):431-436.
30. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. New Engl J Med. 2002;347(18):1403-1411. http://www.nejm.org/doi/pdf/10.1056/NEJMoa021266 (May 28, 2013)
31. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
32. Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H, Mimemoto M. Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling. Drugs Aging 2011;28(10):831-841.
33. Ma RCW, Chan JCN. Type 1 diabetes. In: Schenck-Gustafsson K, DeCola PR, Pfaff DW, Pisetsky DS, eds. Handbook of Clinical Gender Medicine. Basel: Karger, 2012:268-272.
34. Chamnan P, Ma RCW, Chan JCN. Type 2 diabetes. In: Schenck-Gustafsson K, DeCola PR, Pfaff DW, Pisetsky DS, eds. Handbook of Clinical Gender Medicine. Basel: Karger, 2012:273-282.
35. Chamnan P, Simmons RK, Khaw KT, Wareham NJ, Griffin SJ. Estimating the potential population impact of stepwise screening strategies for identifying and treating individuals at high risk of Type 2 diabetes: a modelling study. Diabet Med 2012;29(7):893-904. http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2012.03609.x/pdf (May 28. 2013)
36. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4-14. http://download.journals.elsevierhealth.com/pdfs/journals/0168-8227/PIIS016882270900432X.pdf (May 28, 2013)
37. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2002;162(15):1737-1745. http://archinte.jamanetwork.com/article.aspx?articleid=754066 (May 28, 2013)